Pancreatic grade 3 neuroendocrine tumors behave similarly to neuroendocrine carcinomas following resection: a multi-center, international appraisal of the WHO 2010 and WHO 2017 staging schema for pancreatic neuroendocrine lesions.


Journal

HPB : the official journal of the International Hepato Pancreato Biliary Association
ISSN: 1477-2574
Titre abrégé: HPB (Oxford)
Pays: England
ID NLM: 100900921

Informations de publication

Date de publication:
09 2020
Historique:
received: 06 07 2019
accepted: 28 12 2019
pubmed: 23 2 2020
medline: 26 10 2021
entrez: 22 2 2020
Statut: ppublish

Résumé

In 2017, the WHO updated their 2010 classification of pancreatic neuroendocrine tumors, introducing a well-differentiated, highly proliferative grade 3 tumor, distinct from neuroendocrine carcinomas. The aim of this study was to investigate the clinical significance of this update in a large cohort of resected tumors. Using a multicenter, international dataset of patients with pancreatic neuroendocrine lesions, patients were classified both according to the WHO 2010 and 2017 schema. Multivariable survival analyses were performed, and the models were evaluated for discrimination ability and goodness of fit. Excluding patients with a known germline MEN1 mutation and incomplete data, 544 patients were analyzed. The performance of the WHO 2010 and 2017 models was similar, however surgically resected grade 3 tumors behaved very similarly to neuroendocrine carcinomas. The addition of a grade 3 NET classification may be of limited utility in surgically resected patients, as these lesions have similar postoperative survival compared to carcinomas. While the addition may allow for a more granular evaluation of novel treatment strategies, surgical intervention for high grade tumors should be considered judiciously.

Sections du résumé

BACKGROUND
In 2017, the WHO updated their 2010 classification of pancreatic neuroendocrine tumors, introducing a well-differentiated, highly proliferative grade 3 tumor, distinct from neuroendocrine carcinomas. The aim of this study was to investigate the clinical significance of this update in a large cohort of resected tumors.
METHODS
Using a multicenter, international dataset of patients with pancreatic neuroendocrine lesions, patients were classified both according to the WHO 2010 and 2017 schema. Multivariable survival analyses were performed, and the models were evaluated for discrimination ability and goodness of fit.
RESULTS
Excluding patients with a known germline MEN1 mutation and incomplete data, 544 patients were analyzed. The performance of the WHO 2010 and 2017 models was similar, however surgically resected grade 3 tumors behaved very similarly to neuroendocrine carcinomas.
CONCLUSION
The addition of a grade 3 NET classification may be of limited utility in surgically resected patients, as these lesions have similar postoperative survival compared to carcinomas. While the addition may allow for a more granular evaluation of novel treatment strategies, surgical intervention for high grade tumors should be considered judiciously.

Identifiants

pubmed: 32081540
pii: S1365-182X(20)30001-0
doi: 10.1016/j.hpb.2019.12.014
pii:
doi:

Substances chimiques

OMS 2017 0
Organic Chemicals 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1359-1367

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 International Hepato-Pancreato-Biliary Association Inc. All rights reserved.

Auteurs

Patrick J Worth (PJ)

Stanford University, United States. Electronic address: patrick.worth@gmail.com.

Julie Leal (J)

University of Toronto, Canada.

Qian Ding (Q)

Stanford University, United States.

Amber Trickey (A)

Stanford University, United States.

Monica M Dua (MM)

Stanford University, United States.

Nikolaos Chatzizacharias (N)

University of Cambridge and Addenbrooke's Hospital, United Kingdom.

Zahir Soonawalla (Z)

University of Oxford, United Kingdom.

Panagiotis Athanasopoulos (P)

University College London, Royal Free Hospitals, United Kingdom.

Christos Toumpanakis (C)

University College London, Royal Free Hospitals, United Kingdom.

Paul Hansen (P)

Providence Portland Cancer Center, United States.

Rowan W Parks (RW)

University of Edinburgh, United Kingdom.

Saxon Connor (S)

Canerbury District Health Board, New Zealand.

Kate Parker (K)

University of Auckland, New Zealand.

Jonathan Koea (J)

University of Auckland, New Zealand.

Sanket Srinavasa (S)

University of Auckland, New Zealand.

Benedetto Ielpo (B)

Hospital Universitario Madrid, Spain.

Emilio Vicente Lopez (E)

Hospital Universitario Madrid, Spain.

Benjamin Lawrence (B)

University of Auckland, New Zealand.

Brendan C Visser (BC)

Stanford University, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH